Literature DB >> 16195872

Cannabinoid CB1 receptor-mediated inhibition of noradrenaline release in guinea-pig vessels, but not in rat and mouse aorta.

T Schultheiss1, K Flau, M Kathmann, M Göthert, E Schlicker.   

Abstract

Cannabinoids exert complex effects on blood pressure related to their interference with cardiovascular centres in the central nervous system and to their direct influence on vascular muscle, vascular endothelium and heart. In view of the relative lack of information on the occurrence of CB1 receptors on the vascular postganglionic sympathetic nerve fibres, the aim of the present study was to examine whether cannabinoid receptor ligands affect the electrically evoked tritium overflow in superfused vessels (tissue pieces) from the guinea-pig, the rat and the mouse preincubated with 3H-noradrenaline. The cannabinoid receptor agonist WIN 55,212-2 (R(+)-[2,3-dihydro-5-methyl-3-[(morpholinyl)methyl]-pyrrolo[1,2,3-de]1,4-benzoxazinyl](1-naphthalenyl) methanone) inhibited the evoked tritium overflow in the guinea-pig aorta, but not in that of the rat or mouse. The concentration-response curve of WIN 55,212-2 was shifted to the right by the CB1 receptor antagonist rimonabant, yielding an apparent pA2 value of 7.9. The most pronounced (near-maximum) inhibition obtained at the highest WIN 55,212-2 concentration applied (3.2 microM) amounted to 40%. WIN 55,212-2 also inhibited the evoked overflow in guinea-pig pulmonary artery, basilar artery and portal vein, again in a manner sensitive to antagonism by rimonabant. The latter did not affect the evoked overflow by itself in the four vessels, but did increase the electrically evoked tritium overflow from superfused guinea-pig hippocampal slices preincubated with 3H-choline and from superfused guinea-pig retina discs preincubated with 3H-noradrenaline (labelling dopaminergic cells in this tissue). The inhibitory effect of 3.2 microM WIN 55,212-2 on the evoked overflow from the guinea-pig aorta was comparable in size to that obtained with agonists at the histamine H3, kappa opioid (KOP) and ORL1 (NOP) receptor (1 or 10 microM, producing the respective near-maximum effects) whereas prostaglandin E2 1 microM caused a higher near-maximum inhibition of 70%. Prostaglandin E2 also induced an inhibition by 65 and 80% in the rat and mouse aorta respectively, indicating that the present conditions are basically suitable for detecting presynaptic receptor-mediated inhibition of noradrenaline release. The results show that the postganglionic sympathetic nerve fibres in the guinea-pig aorta, but not in the rat or mouse aorta, are endowed with presynaptic inhibitory cannabinoid CB1 receptors; such receptors also occur in guinea-pig pulmonary artery, basilar artery and portal vein. These CB1 receptors are not subject to an endogenous tone and the extent of inhibition obtainable via these receptors is within the same range as that of several other presynaptic heteroreceptors, but markedly lower than that obtainable via receptors for prostaglandin E2.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195872     DOI: 10.1007/s00210-005-0007-4

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  34 in total

1.  Production and physiological actions of anandamide in the vasculature of the rat kidney.

Authors:  D G Deutsch; M S Goligorsky; P C Schmid; R J Krebsbach; H H Schmid; S K Das; S K Dey; G Arreaza; C Thorup; G Stefano; L C Moore
Journal:  J Clin Invest       Date:  1997-09-15       Impact factor: 14.808

Review 2.  Modulation of transmitter release via presynaptic cannabinoid receptors.

Authors:  E Schlicker; M Kathmann
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

3.  Cannabinoid CB1 receptor of cat cerebral arterial muscle functions to inhibit L-type Ca2+ channel current.

Authors:  D Gebremedhin; A R Lange; W B Campbell; C J Hillard; D R Harder
Journal:  Am J Physiol       Date:  1999-06

Review 4.  Effects of cannabinoids on neurotransmission.

Authors:  B Szabo; E Schlicker
Journal:  Handb Exp Pharmacol       Date:  2005

5.  Effect of the cannabinoid receptor agonist WIN55212-2 on sympathetic cardiovascular regulation.

Authors:  N Niederhoffer; B Szabo
Journal:  Br J Pharmacol       Date:  1999-01       Impact factor: 8.739

6.  Cannabinoid receptor-mediated inhibition of dopamine release in the retina.

Authors:  E Schlicker; J Timm; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-12       Impact factor: 3.000

7.  Nociceptin inhibits noradrenaline release in the mouse brain cortex via presynaptic ORL1 receptors.

Authors:  E Schlicker; S Werthwein; M Kathmann; U Bauer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1998-10       Impact factor: 3.000

8.  Prostanoid receptors of the EP3 subtype mediate the inhibitory effect of prostaglandin E2 on noradrenaline release in the mouse brain cortex.

Authors:  H J Exner; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-01       Impact factor: 3.000

9.  Cannabinoids acting on CB1 receptors decrease contractile performance in human atrial muscle.

Authors:  Andreas Bonz; Martin Laser; Sina Küllmer; Silke Kniesch; Jörg Babin-Ebell; Verena Popp; Georg Ertl; Jens Andreas Wagner
Journal:  J Cardiovasc Pharmacol       Date:  2003-04       Impact factor: 3.105

10.  Cannabinoids inhibit pre- and postjunctionally sympathetic neurotransmission in rat mesenteric arteries.

Authors:  Vera Ralevic; David A Kendall
Journal:  Eur J Pharmacol       Date:  2002-05-31       Impact factor: 4.432

View more
  6 in total

Review 1.  Triphasic blood pressure responses to cannabinoids: do we understand the mechanism?

Authors:  Barbara Malinowska; Marta Baranowska-Kuczko; Eberhard Schlicker
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors.

Authors:  Brian D Hudson; Terence E Hébert; Melanie E M Kelly
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

3.  O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus.

Authors:  Bernd Jergas; Kirsten Schulte; Laura Bindila; Beat Lutz; Eberhard Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-05-23       Impact factor: 3.000

Review 4.  Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Authors:  Hester van Diepen; Eberhard Schlicker; Martin C Michel
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-07-25       Impact factor: 3.000

Review 5.  Endocannabinoids in the retina: from marijuana to neuroprotection.

Authors:  Stephen Yazulla
Journal:  Prog Retin Eye Res       Date:  2008-08-03       Impact factor: 21.198

Review 6.  Cannabinoids for Treating Cardiovascular Disorders: Putting Together a Complex Puzzle.

Authors:  Basma Ghazi Eid
Journal:  J Microsc Ultrastruct       Date:  2018 Oct-Dec
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.